Jump to:
Matthew's practice focuses on representing public and privately held companies in in a broad range of transactional matters, including mergers and acquisitions, divestitures and carve-outs, licensing and collaboration agreements, joint ventures, royalty monetizations, supply and distribution arrangements, and other complex transactions. He also counsels clients on an assortment of corporate governance and commercial matters.
Prior to joining Ropes & Gray, Matthew was an associate in the corporate group at another leading law firm in New York. Matthew also worked as the associate general counsel for Union Square Hospitality Group.
Experience
- Advised Novo Nordisk in an asset purchase and license agreement with Omeros Corporation for Omeros’ drug candidate zaltenibart, a potential best-in-class treatment for rare blood and kidney disorders, in a deal worth up to $2.1 billion.
- Represented Ligand Pharmaceuticals in the purchase of certain tiered royalties on future sales of AVIM therapy and Virtue SAB, device-based therapies targeting hypertension and arterial disease, from Orchestra BioMed.
- Represented Adaptimmune Therapeutics in the sale of TECELRA, lete-cel, afami-cel, and uza-cel cell therapies to US WorldMed.
- Represented a leading investment management firm in the purchase of certain future tiered royalties and commercial milestones associated with a therapy for the treatment of demodex blepharitis.
- Represented a leading investment management firm in the sale of its royalty interest in a therapy for the treatment of cardiovascular disease.
- Represented Eli Lilly and Company in its $1 billion option to acquire Radionetics Oncology, a biotechnology company discovering and developing novel small molecule G protein coupled receptor (GPCR) targeted radiopharmaceuticals to treat a broad range of solid tumors.
- Represented Regeneron in acquisition of 2seventy Bio platforms to create new R&D unit Regeneron Cell Medicines.
- Represented Johnson & Johnson’s pharmaceuticals business, Janssen Pharmaceuticals, in connection with numerous domestic and cross-border acquisitions and divestitures.
- Represented Johnson & Johnson’s medical device and medical technology businesses, DePuy Synthes and Johnson & Johnson Vision, in connection with numerous domestic and cross-border acquisitions and divestitures.
- Represented Heidelberg Materials in connection with the acquisition of The SEFA Group, Inc., the largest recycler of fly ash sold for use in concrete products in the United States.
- Represented the Milwaukee Bucks on various ongoing corporate and commercial matters.
- Represented Pfizer Inc. in its $11.6 billion acquisition of Biohaven Pharmaceuticals.
- Represented tire distributor Max Finkelstein, Inc. in sale to U.S. AutoForce.
- Represented Medtronic plc in its $1.1 billion acquisition of Intersect ENT, Inc.